Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pneumo 23 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Pneumo 23 |
| Group B | ACTIVE_COMPARATOR | Prevnar |
| Name | Type | Description |
|---|---|---|
| Pneumo 23 | BIOLOGICAL | Vaccine (Pneumo 23) |
| Prevnar | BIOLOGICAL | Vaccine (Prevnar) |
Inclusion Criteria: * Aged 12 to 18 months on the day of inclusion * Informed consent form signed by the parent/legally acceptable representative and by an independent witness if requested by local Ethics Committee regulation or/and if the parent/legally acceptable representative is illiterate * Ch...
Pneumo 23 is a vaccine used for Streptococcus pneumoniae, a bacterium that causes infections such as pneumonia, meningitis, and sepsis. It is being studied in children to assess the immunogenicity and safety of a booster dose. The vaccine is currently in Phase 3 clinical development.
Pneumo 23 is developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in pediatric populations.
Pneumo 23 is in Phase 3 clinical development. A Phase 3 trial has been completed, which evaluated the immunogenicity and safety of a booster dose in children aged 12 to 18 months who were previously primed with Prevnar. The vaccine is investigational and not yet approved.
Pneumo 23 has one completed Phase 3 trial registered under NCT00594347. This trial enrolled 339 participants in Thailand and assessed the immunogenicity and safety of a booster dose in children aged 12 to 18 months primed with Prevnar. The study was randomized, double-blind, and active-controlled.
No, Pneumo 23 is classified as a vaccine, not a monoclonal antibody. It is designed to prevent Streptococcus pneumoniae infections by stimulating the immune system. The vaccine is being studied in a Phase 3 clinical trial to evaluate its safety and immunogenicity in children.